Key Facts about TRIAD

TRIAD Clinical Trial

Dog Aging Project
Longer, healthier lives. Together.

- The *Test of Rapamycin in Aging Dogs* (TRIAD) is **a double-blind, placebo controlled, clinical trial of the medicine rapamycin** being conducted by the Dog Aging Project.
- Rapamycin is an immunosuppressive and adjunctive chemotherapeutic at high doses. At lower doses it modifies cellular energy sensing and metabolism, and has been shown to **increase the lifespan** and **delay or reverse many age-related disorders** in mice.
- The primary purpose of this project is to determine whether rapamycin increases the lifespan of companion dogs; the primary endpoint is survival from the time of enrollment.
    - o A secondary purpose is to determine whether rapamycin improves various measures of health in aging dogs.
        - o **Secondary endpoints of the Cardiac Arm** include cardiac health as assessed by cardiac exam, ECG, echocardiography and blood pressure measurement.
    - o **Secondary endpoints of the Neurologic Arm** include locomotor and neurocognitive health as assessed by neurologic exam, owner-reported measures of behavior and cognitive tasks, and potential additional in-clinic cognitive assessments.
- **Lead researchers and consultants on the Dog Aging Project and TRIAD** include:
    - **Dr. Kate E. Creevy**, DVM, MS, DACVIM (SAIM), Professor, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University
    - **Dr. May Reed**, MD, Professor, Department of Medicine, University of Washington School of Medicine
    - **Dr. Rozalyn Anderson**, PhD, Professor, Department of Medicine, University of Wisconsin School of Medicine and Public Health
    - **Dr. Daniel Promislow**, DPhil, Senior Scientist and Scientific Advisor, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University
    - **Dr. Mandy Coleman**, DVM, DACVIM (Cardiology), Associate Professor, College of Veterinary Medicine, University of Georgia
    - **Dr. Stephanie McGrath**, DVM, MS, DACVIM (Neurology), Associate Professor, College of Veterinary Medicine, Colorado State University
    - **Dr. Natasha Olby**, Vet MB, PhD, MRCVS, DACVIM (Neurology), Professor, College of Veterinary Medicine, North Carolina State University
- **TRIAD is funded by the National Institute on Aging (NIA)**, a part of the National Institutes of Health (NIH), and by philanthropic donation.
- TRIAD is overseen by the Institutional Animal Care and Use Committee (IACUC) and

the Clinical Research Review Committee (CRRC) at Texas A&M University College of Veterinary Medicine & Biomedical Sciences, and an NIH-constituted Data and Safety Monitoring Board. Each participating site ensures acceptance of the protocol by its local oversight bodies (IACUC and/or CRRC, or similar).

- Eligible dogs must be **at least 7 years of age and at least 44 pounds (20 kg)** in weight , and **generally healthy for their age.** Owners must be willing to bring their dogs to one of our participating clinical sites for an initial screening / baseline examination, and then twice yearly for three years.
- Dogs must be cooperative for examination, including blood collection and any required diagnostic examinations without sedation, and must have normal diagnostic findings at the time of enrollment.
- Each enrolled dog will receive either **rapamycin or placebo for a period of 1 year.** Dogs will be monitored twice yearly during that year and for an additional 2 years after the study medication is stopped.
- Sites participating in this trial include both academic hospitals and private or corporate specialty hospitals across the United States.
- Recruitment, medical records eligibility review, Informed Consent, screening examination scheduling, assessment of screening data for enrollment, and randomization are **performed centrally by the Dog Aging Project TRIAD team**.
- Biospecimen collection kits with instructions and prepaid shipping labels are provided to each owner for each visit, so that assays, processing and biobanking can be performed by the Dog Aging Project team.
- Step-by-step clinical visit checklists are provided for each visit. Completed visit reports are returned to the Dog Aging Project for entry into our centralized REDCap database.
- **Site-specific local fees** are charged for all study-related examinations and procedures, as agreed in advance, and are paid by TRIAD. Study medications are provided to clinical sites in pre-packaged 6-month dosing kits, identified by a code that indicates drug (rapamycin or placebo) and size category.
- The Dog Aging Project is an **Open Science project**, however, data from the TRIAD clinical trial specifically will not be released until the study has concluded.